Although the harmful effects of smoking after a cancer diagnosis have been clearly demonstrated, many patients continue to smoke cigarettes during treatment and beyond. The NCCN Guidelines for Smoking Cessation emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based recommendations tailored to the unique needs and concerns of patients with cancer. The recommendations contained herein describe interventions for cessation of all combustible tobacco products (eg, cigarettes, cigars, hookah), including smokeless tobacco products. However, recommendations are based on studies of cigarette smoking. The NCCN Smoking Cessation Panel recommends that treatment plans for all patients with cancer who smoke include the following 3 tenets that should be done concurrently: (1) evidence-based motivational strategies and behavior therapy (counseling), which can be brief; (2) evidence-based pharmacotherapy; and (3) close follow-up with retreatment as needed.
Individual Disclosures for the NCCN Smoking Cessation Panel
CDC. CDC Vital Signs: Cancer and tobacco use. Accessed January 12, 2023. Available at: https://www.cdc.gov/vitalsigns/pdf/2016-11-vitalsigns.pdf)| false
Lortet-TieulentJ, Goding SauerA, SiegelRL, et al.State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern Med2016;176:1792–1798.
Lortet-TieulentJ, Goding SauerA, SiegelRL, State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern Med 2016;176:1792–1798.27775761)| false
TaoL, WangR, GaoYT, et al.Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study. Cancer Epidemiol Biomarkers Prev2013;22:2404–2411.
TaoL, WangR, GaoYT, Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study. Cancer Epidemiol Biomarkers Prev 2013;22:2404–2411.)| false
PassarelliMN, NewcombPA, HamptonJM, et al.Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and smoking-related diseases. J Clin Oncol2016;34:1315–1322.
PassarelliMN, NewcombPA, HamptonJM, Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and smoking-related diseases. J Clin Oncol 2016;34:1315–1322.26811527)| false
U.S. Department of Health & Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Accessed January 23, 2023. Available at: https://www.hhs.gov/sites/default/files/consequences-smoking-exec-summary.pdf24455788)| false
WarrenGW, CartmellKB, Garrett-MayerE, et al.Attributable failure of first-line cancer treatment and incremental costs associated with smoking by patients with cancer. JAMA Netw Open2019;2:e191703.
WarrenGW, CartmellKB, Garrett-MayerE, Attributable failure of first-line cancer treatment and incremental costs associated with smoking by patients with cancer. JAMA Netw Open 2019;2:e191703.30951159)| false
UnderwoodJM, TownsendJS, TaiE, et al.Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv2012;6:333–344.
UnderwoodJM, TownsendJS, TaiE, Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv 2012;6:333–344.22706885)| false
ParsonsA, DaleyA, BeghR, et al.Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ2010;340:b5569.
ParsonsA, DaleyA, BeghR, Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.20093278)| false
SheikhM, MukeriyaA, ShanginaO, et al.Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality: a prospective cohort study. Ann Intern Med2021;174:1232–1239.
SheikhM, MukeriyaA, ShanginaO, Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality: a prospective cohort study. Ann Intern Med 2021;174:1232–1239.34310171)| false
BaserS, ShannonVR, EapenGA, et al.Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest2006;130:1784–1790.
BaserS, ShannonVR, EapenGA, Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006;130:1784–1790.17166997)| false
CarrollAJ, Veluz-WilkinsAK, BlazekovicS, et al.Cancer-related disease factors and smoking cessation treatment: analysis of an ongoing clinical trial. Psychooncology2018;27:471–476.
GritzER, FingeretMC, VidrineDJ, Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 2006;106:17–27.16311986)| false
WestmaasJL, NewtonCC, StevensVL, et al.Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J Clin Oncol2015;33:1647–1652.
WestmaasJL, NewtonCC, StevensVL, Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J Clin Oncol 2015;33:1647–1652.25897151)| false
AveyardP, BeghR, ParsonsA, et al.Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction2012;107:1066–1073.
AveyardP, BeghR, ParsonsA, Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction 2012;107:1066–1073.)| false
LeeSM, LandryJ, JonesPM, et al.The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. Anesth Analg2013;117:605–613.
LeeSM, LandryJ, JonesPM, The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. Anesth Analg 2013;117:605–613.)| false
CDC. American Indians/Alaska Natives and tobacco use: health disparities and ways to advance health equity. Accessed January 12, 2023. Available at: https://www.cdc.gov/tobacco/disparities/american-indians/index.htm)| false
TollBA, BrandonTH, GritzER, et al.Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res2013;19:1941–1948.
TollBA, BrandonTH, GritzER, Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013;19:1941–1948.)| false
LandSR, TollBA, MoinpourCM, et al.Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res2016;22:1907–1913.
LandSR, TollBA, MoinpourCM, Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res 2016;22:1907–1913.26888828)| false
GoldsteinAO, Ripley-MoffittCE, PathmanDE, et al.Tobacco use treatment at the U.S. National Cancer Institute’s designated Cancer Centers. Nicotine Tob Res2013;15:52–58.
GoldsteinAO, Ripley-MoffittCE, PathmanDE, Tobacco use treatment at the U.S. National Cancer Institute’s designated Cancer Centers. Nicotine Tob Res 2013;15:52–58.22499079)| false
PetersEN, TorresE, TollBA, et al.Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program clinical trials. J Clin Oncol2012;30:2869–2875.
PetersEN, TorresE, TollBA, Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program clinical trials. J Clin Oncol 2012;30:2869–2875.22689794)| false
SiegelDA, HenleySJ, WikeJM, et al.Capture of tobacco use among population-based registries: findings from 10 National Program of Cancer Registries states. Cancer2018;124:2381–2389.
SiegelDA, HenleySJ, WikeJM, Capture of tobacco use among population-based registries: findings from 10 National Program of Cancer Registries states. Cancer 2018;124:2381–2389.29579317)| false
GritzER, DreslerC, SarnaL. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev2005;14:2287–2293.
GritzER, DreslerC, SarnaL. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287–2293.16214906)| false
BakerTB, PiperME, McCarthyDE, et al.Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res2007;9(Suppl 4):S555–570.
BakerTB, PiperME, McCarthyDE, Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res 2007;9(Suppl 4):S555–570.18067032)| false
HeathertonTF, KozlowskiLT, FreckerRC, et al.The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict1991;86:1119–1127.
HeathertonTF, KozlowskiLT, FreckerRC, The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119–1127.1932883)| false
Lindson-HawleyN, Hartmann-BoyceJ, FanshaweTR, et al.Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev2016;10:CD005231.
LeoneFT, ZhangY, Evers-CaseyS, et al.Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med2020;202:e5–31.
LeoneFT, ZhangY, Evers-CaseyS, Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;202:e5–31.32663106)| false
Lindson-HawleyN, AveyardP, HughesJR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012;11:CD008033.23152252)| false
Lindson-HawleyN, AveyardP, HughesJR. Gradual reduction vs abrupt cessation as a smoking cessation strategy in smokers who want to quit. JAMA2013;310:91–92.
Lindson-HawleyN, AveyardP, HughesJR. Gradual reduction vs abrupt cessation as a smoking cessation strategy in smokers who want to quit. JAMA 2013;310:91–92.23821093)| false
OstroffJS, BurkhalterJE, CinciripiniPM, et al.Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. Health Psychol2014;33:737–747.
OstroffJS, BurkhalterJE, CinciripiniPM, Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. Health Psychol 2014;33:737–747.23895203)| false
ReidMS, JiangH, FallonB, et al.Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. Am J Drug Alcohol Abuse2011;37:472–478.
ReidMS, JiangH, FallonB, Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. Am J Drug Alcohol Abuse 2011;37:472–478.21854292)| false
DitreJW, HeckmanBW, LaRoweLR, Pain status as a predictor of smoking cessation initiation, lapse, and relapse. Nicotine Tob Res 2021;23:186–194.32594124)| false
VijayaraghavanM, PenkoJ, VittinghoffE, et al.Smoking behaviors in a community-based cohort of HIV-infected indigent adults. AIDS Behav2014;18:535–543.
VijayaraghavanM, PenkoJ, VittinghoffE, Smoking behaviors in a community-based cohort of HIV-infected indigent adults. AIDS Behav 2014;18:535–543.)| false
EhlersSL, BronarsCA, PattenCA, et al.Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplant2014;49:961–965.
EhlersSL, BronarsCA, PattenCA, Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplant 2014;49:961–965.24732958)| false
HaldJ, OvergaardJ, GrauC. Evaluation of objective measures of smoking status--a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol2003;42:154–159.
HaldJ, OvergaardJ, GrauC. Evaluation of objective measures of smoking status--a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol 2003;42:154–159.)| false
WarrenGW, ArnoldSM, ValentinoJP, et al.Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol2012;103:45–48.
WarrenGW, ArnoldSM, ValentinoJP, Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol 2012;103:45–48.)| false
SteadLF, KoilpillaiP, LancasterT. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev2015;10:CD009670.
SteadLF, KoilpillaiP, LancasterT. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2015;10:CD009670.)| false
LeyroTM, HallSM, HickmanN, et al.Clinical management of tobacco dependence in inpatient psychiatry: provider practices and patient utilization. Psychiatr Serv2013;64:1161–1165.
CrawfordG, WeisbrotJ, BastianJ, et al.Predictors of varenicline adherence among cancer patients treated for tobacco dependence and its association with smoking cessation. Nicotine Tob Res2018;21:1135–1139.
CrawfordG, WeisbrotJ, BastianJ, Predictors of varenicline adherence among cancer patients treated for tobacco dependence and its association with smoking cessation. Nicotine Tob Res 2018;21:1135–1139.)| false
ThomasKH, MartinRM, DaviesNM, et al.Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ2013;347:f5704.
ThomasKH, MartinRM, DaviesNM, Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 2013;347:f5704.24124105)| false
ThomasKH, MartinRM, KnipeDW, et al.Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ2015;350:h1109.
HollandsGJ, McDermottMS, Lindson-HawleyN, et al.Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev2015;2015:CD009164.
HollandsGJ, McDermottMS, Lindson-HawleyN, Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev 2015;2015:CD009164.)| false
PacekLR, McClernonFJ, BosworthHB. Adherence to pharmacological smoking cessation interventions: a literature review and synthesis of correlates and barriers. Nicotine Tob Res2018;20:1163–1172.
PacekLR, McClernonFJ, BosworthHB. Adherence to pharmacological smoking cessation interventions: a literature review and synthesis of correlates and barriers. Nicotine Tob Res 2018;20:1163–1172.)| false
CahillK, StevensS, PereraR, et al.Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev2013;2013:CD009329.
MillsEJ, WuP, LockhartI, et al.Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med2012;44:588–597.
MillsEJ, WuP, LockhartI, Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012;44:588–597.22860882)| false
Livingstone-BanksJ, LindsonN, Hartmann-BoyceJ, et al.Effects of interventions to combat tobacco addiction: Cochrane update of 2019 and 2020 reviews. Addiction2022;117:1573–1588.
Livingstone-BanksJ, LindsonN, Hartmann-BoyceJ, Effects of interventions to combat tobacco addiction: Cochrane update of 2019 and 2020 reviews. Addiction 2022;117:1573–1588.34859525)| false
AnthenelliRM, BenowitzNL, WestR, et al.Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet2016;387:2507–2520.
AnthenelliRM, BenowitzNL, WestR, Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507–2520.)| false
PriceS, HitsmanB, Veluz-WilkinsA, et al.The use of varenicline to treat nicotine dependence among patients with cancer. Psychooncology2017;26:1526–1534.
PriceS, HitsmanB, Veluz-WilkinsA, The use of varenicline to treat nicotine dependence among patients with cancer. Psychooncology 2017;26:1526–1534.27218657)| false
EbbertJO, HughesJR, WestRJ, et al.Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA2015;313:687–694.
EbbertJO, HughesJR, WestRJ, Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015;313:687–694.25688780)| false
TonstadS, TønnesenP, HajekP, et al.Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA2006;296:64–71.
TonstadS, TønnesenP, HajekP, Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64–71.16820548)| false
BakerTB, PiperME, SmithSS, et al.Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial. JAMA2021;326:1485–1493.
BakerTB, PiperME, SmithSS, Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial. JAMA 2021;326:1485–1493.34665204)| false
GonzalesD, HajekP, PliammL, et al.Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther2014;96:390–396.
GonzalesD, HajekP, PliammL, Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther 2014;96:390–396.24911368)| false
HajekP, McRobbieH, Myers SmithK, et al.Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. JAMA Intern Med2015;175:266–271.
HajekP, McRobbieH, Myers SmithK, Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. JAMA Intern Med 2015;175:266–271.25545858)| false
Karam-HageM, KypriotakisG, RobinsonJD, et al.Improvement of smoking abstinence rates with increased varenicline dosage: a propensity score-matched analysis. J Clin Psychopharmacol2018;38:34–41.
Jiménez-RuizCA, BarriosM, PeñaS, et al.Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc2013;88:1443–1445.
Jiménez-RuizCA, BarriosM, PeñaS, Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc 2013;88:1443–1445.24290118)| false
JorenbyDE, HaysJT, RigottiNA, et al.Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA2006;296:56–63.
JorenbyDE, HaysJT, RigottiNA, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.)| false
WilliamsKE, ReevesKR, BillingCBJr, et al.A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin2007;23:793–801.
WilliamsKE, ReevesKR, BillingCBJr, A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793–801.17407636)| false
AnthenelliRM, MorrisC, RameyTS, et al.Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med2013;159:390–400.
AnthenelliRM, MorrisC, RameyTS, Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013;159:390–400.)| false
ProchaskaJJ, HiltonJF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ2012;344:e2856.
ProchaskaJJ, HiltonJF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.22563098)| false
SvanströmH, PasternakB, HviidA. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ2012;345:e7176.
SvanströmH, PasternakB, HviidA. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012;345:e7176.23138033)| false
MillsEJ, ThorlundK, EapenS, et al.Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation2014;129:28–41.
SinghS, LokeYK, SpanglerJG, et al.Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ2011;183:1359–1366.
SinghS, LokeYK, SpanglerJG, Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359–1366.21727225)| false
CDC. Smoking cessation: a report of the surgeon general. Accessed January 12, 2023. Available at https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/index.html)| false
KotzD, ViechtbauerW, SimpsonC, et al.Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med2015;3:761–768.
KotzD, ViechtbauerW, SimpsonC, Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015;3:761–768.26355008)| false
SmithSS, McCarthyDE, JapuntichSJ, et al.Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med2009;169:2148–2155.
SmithSS, McCarthyDE, JapuntichSJ, Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009;169:2148–2155.20008701)| false
BenowitzNL, JacobPIII, FongI, et al.Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther1994;268:296–303.
BenowitzNL, PorchetH, SheinerL, et al.Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther1988;44:23–28.
MillsEJ, WuP, LockhartI, et al.Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis2010;8:8.
MillsEJ, WuP, LockhartI, Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010;8:8.)| false
KimmelSE, BerlinJA, MilesC, et al.Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol2001;37:1297–1302.
KimmelSE, BerlinJA, MilesC, Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001;37:1297–1302.)| false
HubbardR, LewisS, SmithC, et al.Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control2005;14:416–421.
HubbardR, LewisS, SmithC, Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005;14:416–421.16319366)| false
MeineTJ, PatelMR, WashamJB, et al.Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol2005;95:976–978.
MeineTJ, PatelMR, WashamJB, Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005;95:976–978.15820167)| false
Martínez-GarcíaE, IrigoyenM, González-MorenoO, et al.Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci2010;116:467–476.
Martínez-GarcíaE, IrigoyenM, González-MorenoO, Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 2010;116:467–476.20457658)| false
NishiokaT, LuoLY, ShenL, et al.Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer2014;110:1785–1792.
NishiokaT, LuoLY, ShenL, Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 2014;110:1785–1792.24548862)| false
ZhangJ, KamdarO, LeW, et al.Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am J Respir Cell Mol Biol2009;40:135–146.
TreviñoJG, PillaiS, KunigalS, et al.Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia2012;14:1102–1114.
TreviñoJG, PillaiS, KunigalS, Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia 2012;14:1102–1114.)| false
MaierCR, HollanderMC, HobbsEA, et al.Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila)2011;4:1743–1751.
MaierCR, HollanderMC, HobbsEA, Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila) 2011;4:1743–1751.)| false
MurphySE, von WeymarnLB, SchuttenMM, et al.Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. Cancer Prev Res (Phila)2011;4:1752–1760.
MurphySE, von WeymarnLB, SchuttenMM, Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. Cancer Prev Res (Phila) 2011;4:1752–1760.)| false
StepanovI, CarmellaSG, BriggsA, et al.Presence of the carcinogen N′-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res2009;69:8236–8240.
StepanovI, CarmellaSG, BriggsA, Presence of the carcinogen N′-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236–8240.19843845)| false
MurrayRP, ConnettJE, ZapawaLM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009;11:1076–1082.19571249)| false
KoegelenbergCF, NoorF, BatemanED, et al.Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA2014;312:155–161.
KoegelenbergCF, NoorF, BatemanED, Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014;312:155–161.25005652)| false
RamonJM, MorchonS, BaenaA, et al.Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med2014;12:172.
RamonJM, MorchonS, BaenaA, Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med 2014;12:172.25296623)| false
HajekP, SmithKM, DhanjiAR, et al.Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med2013;11:140.
HajekP, SmithKM, DhanjiAR, Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med 2013;11:140.)| false
StapletonJ, WestR, HajekP, et al.Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction2013;108:2193–2201.
StapletonJ, WestR, HajekP, Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 2013;108:2193–2201.23859696)| false
JorenbyDE, LeischowSJ, NidesMA, et al.A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med1999;340:685–691.
JorenbyDE, LeischowSJ, NidesMA, A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–691.)| false
EvinsAE, CatherC, CulhaneMA, et al.A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol2007;27:380–386.
EvinsAE, CatherC, CulhaneMA, A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007;27:380–386.)| false
van der MeerRM, WillemsenMC, SmitF, et al.Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev2013;2013:CD006102.
van der MeerRM, WillemsenMC, SmitF, Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013;2013:CD006102.)| false
HaysJT, HurtRD, RigottiNA, et al.Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med2001;135:423–433.
HaysJT, HurtRD, RigottiNA, Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001;135:423–433.11560455)| false
Prescribing information for bupropion hydrochloride sustained-release tablets, for oral use. 2020. Accessed May 5, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020358s064lbl.pdf)| false
BinkhorstL, MathijssenRH, van Herk-SukelMP, et al.Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat2013;139:923–929.
BinkhorstL, MathijssenRH, van Herk-SukelMP, Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 2013;139:923–929.23760858)| false
EnglischS, MorgenK, Meyer-LindenbergA, et al.Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Clin Neuropharmacol2013;36:203–215.
EnglischS, MorgenK, Meyer-LindenbergA, Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Clin Neuropharmacol 2013;36:203–215.24201231)| false
RoseJE, BehmFM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry2014;171:1199–1205.
RoseJE, BehmFM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 2014;171:1199–1205.)| false
EbbertJO, HatsukamiDK, CroghanIT, et al.Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA2014;311:155–163.
EbbertJO, HatsukamiDK, CroghanIT, Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014;311:155–163.24399554)| false
CinciripiniPM, MinnixJA, GreenCE, et al.An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Addiction2018;113:1673–1682.
CinciripiniPM, MinnixJA, GreenCE, An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Addiction 2018;113:1673–1682.)| false
ConroyMB, MajchrzakNE, ReganS, et al.The association between patient-reported receipt of tobacco intervention at a primary care visit and smokers’ satisfaction with their health care. Nicotine Tob Res2005; 7(Suppl 1):S29–34.
ConroyMB, MajchrzakNE, ReganS, The association between patient-reported receipt of tobacco intervention at a primary care visit and smokers’ satisfaction with their health care. Nicotine Tob Res 2005; 7(Suppl 1):S29–34.)| false
KlempI, SteffenssenM, BakholdtV, et al.Counseling is effective for smoking cessation in head and neck cancer patients - a systematic review and meta-analysis. J Oral Maxillofac Surg2016;74:1687–1694.
KlempI, SteffenssenM, BakholdtV, Counseling is effective for smoking cessation in head and neck cancer patients - a systematic review and meta-analysis. J Oral Maxillofac Surg 2016;74:1687–1694.26973223)| false
ParkER, PerezGK, ReganS, et al.Effect of sustained smoking cessation counseling and provision of medication vs shorter-term counseling and medication advice on smoking abstinence in patients recently diagnosed with cancer. JAMA2020;324:1406–1418.
ParkER, PerezGK, ReganS, Effect of sustained smoking cessation counseling and provision of medication vs shorter-term counseling and medication advice on smoking abstinence in patients recently diagnosed with cancer. JAMA 2020;324:1406–1418.33048154)| false
SiuAL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2015;163:622–634.
SiuAL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:622–634.26389730)| false
HerdN, BorlandR. The natural history of quitting smoking: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction2009;104:2075–2087.
HerdN, BorlandR. The natural history of quitting smoking: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 2009;104:2075–2087.19922573)| false
WangMP, LiWH, CheungYT, et al.Brief advice on smoking reduction versus abrupt quitting for smoking cessation in Chinese smokers: a cluster randomized controlled trial. Nicotine Tob Res2017;20:67–72.
WangMP, LiWH, CheungYT, Brief advice on smoking reduction versus abrupt quitting for smoking cessation in Chinese smokers: a cluster randomized controlled trial. Nicotine Tob Res 2017;20:67–72.28182243)| false
LiWH, WangMP, HoKY, et al.Helping cancer patients quit smoking using brief advice based on risk communication: a randomized controlled trial. Sci Rep2018;8:2712.
LiWH, WangMP, HoKY, Helping cancer patients quit smoking using brief advice based on risk communication: a randomized controlled trial. Sci Rep 2018;8:2712.29426956)| false
HallSM, HumfleetGL, MuñozRF, et al.Using extended cognitive behavioral treatment and medication to treat dependent smokers. Am J Public Health2011;101:2349–2356.
HallSM, HumfleetGL, MuñozRF, Using extended cognitive behavioral treatment and medication to treat dependent smokers. Am J Public Health 2011;101:2349–2356.21653904)| false
YalcinBM, UnalM, PirdalH, et al.Effects of an anger management and stress control program on smoking cessation: a randomized controlled trial. J Am Board Fam Med2014;27:645–660.
YalcinBM, UnalM, PirdalH, Effects of an anger management and stress control program on smoking cessation: a randomized controlled trial. J Am Board Fam Med 2014;27:645–660.25201934)| false
LiebmannEP, PreacherKJ, RichterKP, Identifying pathways to quitting smoking via telemedicine-delivered care. Health Psychol 2019;38:638–647.31021123)| false
KotsenC, DilipD, Carter-HarrisL, et al.Rapid scaling up of telehealth treatment of tobacco-dependent cancer patients during the COVID-19 outbreak in New York City. Telemed J E Health2021;27:20–29.
KotsenC, DilipD, Carter-HarrisL, Rapid scaling up of telehealth treatment of tobacco-dependent cancer patients during the COVID-19 outbreak in New York City. Telemed J E Health 2021;27:20–29.32649266)| false
BrickerJB, MullKE, McClureJB, et al.Improving quit rates of web-delivered interventions for smoking cessation: full-scale randomized trial of WebQuit.org versus Smokefree.gov. Addiction2018;113:914–923.
FreeC, KnightR, RobertsonS, et al.Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet2011;378:49–55.
FreeC, KnightR, RobertsonS, Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 2011;378:49–55.21722952)| false
AbromsLC, BoalAL, SimmensSJ, A randomized trial of Text2Quit: a text messaging program for smoking cessation. Am J Prev Med 2014;47:242–250.24913220)| false
PrutzmanYM, WisemanKP, GradyMA, et al.Using digital technologies to reach tobacco users who want to quit: evidence from the National Cancer Institute’s Smokefree.gov initiative. Am J Prev Med2021; 60(Suppl 2):S172–184.
PrutzmanYM, WisemanKP, GradyMA, Using digital technologies to reach tobacco users who want to quit: evidence from the National Cancer Institute’s Smokefree.gov initiative. Am J Prev Med 2021; 60(Suppl 2):S172–184.33663705)| false
SampsonL, PapadakosJ, MilneV, Preferences for the provision of smoking cessation education among cancer patients. J Cancer Educ 2018;33:7–11.27075196)| false
SheeranP, JonesK, AvishaiA, What works in smoking cessation interventions for cancer survivors? A meta-analysis. Health Psychol 2019;38:855–865.31259596)| false
MehnertA, KuhntS, BrahlerE, et al.Twelve-month prevalence of mental disorders in cancer patients across major tumor entities. J Clin Oncol2015;33(Suppl):Abstract 9552.
MehnertA, KuhntS, BrahlerE, Twelve-month prevalence of mental disorders in cancer patients across major tumor entities. J Clin Oncol 2015;33(Suppl):Abstract 9552.)| false
SingerS, Das-MunshiJ, BrählerE. Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis. Ann Oncol 2010;21:925–930.19887467)| false
MehnertA, BrählerE, FallerH, et al.Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol2014;32:3540–3546.
MehnertA, BrählerE, FallerH, Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 2014;32:3540–3546.25287821)| false
SchnollRA, MalstromM, JamesC, et al.Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns2002;46:137–145.
SchnollRA, MalstromM, JamesC, Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 2002;46:137–145.11867244)| false
SpencerJC, WheelerSB. A systematic review of Motivational Interviewing interventions in cancer patients and survivors. Patient Educ Couns2016;99:1099–1105.
SpencerJC, WheelerSB. A systematic review of Motivational Interviewing interventions in cancer patients and survivors. Patient Educ Couns 2016;99:1099–1105.26879805)| false
BrandonTH, GoniewiczML, HannaNH, et al.Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol2015;33:952–963.
BrandonTH, GoniewiczML, HannaNH, Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol 2015;33:952–963.)| false
BhatnagarA, WhitselLP, RibislKM, Electronic cigarettes: a policy statement from the American Heart Association. Circulation 2014;130:1418–1436.25156991)| false
American Cancer Society. American Cancer Society position statement on electronic cigarettes. Accessed January 12, 2023. Available at: https://www.cancer.org/healthy/stay-away-from-tobacco/e-cigarette-position-statement.html)| false
KristAH, DavidsonKW, MangioneCM, et al.Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA2021;325:265–279.
KristAH, DavidsonKW, MangioneCM, Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA 2021;325:265–279.33464343)| false
SmithDM, ChristensenC, van BemmelD, et al.Exposure to nicotine and toxicants among dual users of tobacco cigarettes and e-cigarettes: Population Assessment of Tobacco and Health (PATH) study, 2013–2014. Nicotine Tob Res2021;23:790–797.
SmithDM, ChristensenC, van BemmelD, Exposure to nicotine and toxicants among dual users of tobacco cigarettes and e-cigarettes: Population Assessment of Tobacco and Health (PATH) study, 2013–2014. Nicotine Tob Res 2021;23:790–797.33590857)| false
GoniewiczML, SmithDM, EdwardsKC, et al.Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open2018;1:e185937.
GoniewiczML, SmithDM, EdwardsKC, Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open 2018;1:e185937.30646298)| false
HajekP, Phillips-WallerA, PrzuljD, A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:629–637.30699054)| false
SweetL, BraskyTM, CooperS, et al.Quitting behaviors among dual cigarette and e-cigarette users and cigarette smokers enrolled in the tobacco user adult cohort. Nicotine Tob Res2019;21:278–284.
SweetL, BraskyTM, CooperS, Quitting behaviors among dual cigarette and e-cigarette users and cigarette smokers enrolled in the tobacco user adult cohort. Nicotine Tob Res 2019;21:278–284.30346585)| false
ShahabL, GoniewiczML, BlountBC, et al.Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med2017;166:390–400.
ShahabL, GoniewiczML, BlountBC, Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med 2017;166:390–400.28166548)| false
ManzoliL, FlaccoME, FerranteM, Cohort study of electronic cigarette use: effectiveness and safety at 24 months. Tob Control 2017;26:284–292.27272748)| false
ColemanB, RostronB, JohnsonSE, et al.Transitions in electronic cigarette use among adults in the Population Assessment of Tobacco and Health (PATH) study, waves 1 and 2 (2013–2015). Tob Control2019;28:50–59.
ColemanB, RostronB, JohnsonSE, Transitions in electronic cigarette use among adults in the Population Assessment of Tobacco and Health (PATH) study, waves 1 and 2 (2013–2015). Tob Control 2019;28:50–59.29695458)| false
KaszaKA, EdwardsKC, KimmelHL, et al.Association of e-cigarette use with discontinuation of cigarette smoking among adult smokers who were initially never planning to quit. JAMA Netw Open2021;4:e2140880.
KaszaKA, EdwardsKC, KimmelHL, Association of e-cigarette use with discontinuation of cigarette smoking among adult smokers who were initially never planning to quit. JAMA Netw Open 2021;4:e2140880.34962556)| false
KalkhoranS, GlantzSA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med2016;4:116–128.
KalkhoranS, GlantzSA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016;4:116–128.26776875)| false
MalasM, van der TempelJ, SchwartzR, Electronic cigarettes for smoking cessation: a systematic review. Nicotine Tob Res 2016;18:1926–1936.27113014)| false
BrownJ, BeardE, KotzD, et al.Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction2014;109:1531–1540.
BrownJ, BeardE, KotzD, Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014;109:1531–1540.24846453)| false
American Lung Association. E-cigarette or vaping use-associated lung injury (EVALI). Accessed January 12, 2023. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/evali)| false
LaydenJE, GhinaiI, PrayI, Pulmonary illness related to e-cigarette use in Illinois and Wisconsin - final report. N Engl J Med 2020;382:903–916.31491072)| false
BlountBC, KarwowskiMP, ShieldsPG, Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med 2020;382:697–705.31860793)| false
BorderudSP, LiY, BurkhalterJE, et al.Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer2014;120:3527–3535.
BorderudSP, LiY, BurkhalterJE, Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer 2014;120:3527–3535.25252116)| false
AkinboroO, NwabudikeS, EliasR, et al.Electronic cigarette use among survivors of smoking-related cancers in the United States. Cancer Epidemiol Biomarkers Prev2019;28:2087–2094.
AkinboroO, NwabudikeS, EliasR, Electronic cigarette use among survivors of smoking-related cancers in the United States. Cancer Epidemiol Biomarkers Prev 2019;28:2087–2094.31501150)| false
McQueenN, PartingtonEJ, HarringtonKF, et al.Smoking cessation and electronic cigarette use among head and neck cancer patients. Otolaryngol Head Neck Surg2016;154:73–79.
McQueenN, PartingtonEJ, HarringtonKF, Smoking cessation and electronic cigarette use among head and neck cancer patients. Otolaryngol Head Neck Surg 2016;154:73–79.26519457)| false
CorreaJB, BrandonKO, MeltzerLR, et al.Electronic cigarette use among patients with cancer: reasons for use, beliefs, and patient-provider communication. Psychooncology2018;27:1757–1764.
CorreaJB, BrandonKO, MeltzerLR, Electronic cigarette use among patients with cancer: reasons for use, beliefs, and patient-provider communication. Psychooncology 2018;27:1757–1764.29671928)| false
